ADINA Act
- Sponsor
- Rep. Morrison, Kelly [D-MN-3]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Jun 6, 2025
Bottom line
This bill aims to enhance consumer safety by requiring clear allergen and gluten labeling on drug products, mirroring existing food labeling standards.
What it actually does
This bill amends the Federal Food, Drug, and Cosmetic Act to mandate that labels for all human-use drugs must clearly disclose if any ingredient is, or is derived directly or indirectly from, a major food allergen or a gluten-containing grain. It specifically requires identification of each such ingredient and, for gluten, the type of grain.
Proponents argue
Proponents argue this bill closes a critical loophole in consumer protection, as individuals with severe allergies or celiac disease currently lack comprehensive information about drug ingredients, leading to potential adverse reactions. They emphasize that drug labels should provide the same level of transparency as food labels to prevent accidental exposure and ensure patient safety.
Opponents contend
Opponents might argue that implementing these labeling requirements could impose significant compliance costs on pharmaceutical manufacturers, potentially leading to increased drug prices or delays in product availability. They may also contend that the risk of allergic reactions from drug excipients is low and that existing regulatory frameworks are sufficient.
The bill is very short and straightforward, allowing for quick comprehension of its core intent.
Section 2(a), amending Section 502 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352)
Mandatory Allergen and Gluten Labeling for Human Drugs
This provision makes a drug 'misbranded' if its label fails to clearly state and identify any ingredient that is a 'major food allergen' (as defined in existing law) or derived from a 'gluten-containing grain' (like wheat, barley, or rye). This means drug manufacturers would be legally required to list these specific allergens and gluten sources on drug packaging for human-use products, ensuring greater transparency for consumers.
Supporters argue
Supporters argue that this provision is essential for patient safety, providing critical information to individuals who could suffer severe adverse reactions from undisclosed allergens or gluten in medications. They highlight the inconsistency of stringent food labeling rules versus lax drug labeling in this regard, advocating for equal protection.
Critics contend
Critics might argue that the costs associated with identifying all indirect derivatives and re-labeling could be substantial for the pharmaceutical industry, potentially leading to higher drug costs or even the discontinuation of certain less profitable but essential medications due to compliance burdens.
Tradeoffs
The bill balances the enhanced safety and informed choice for consumers with allergies or celiac disease against the potential increased regulatory burden and compliance costs for pharmaceutical manufacturers, which could impact drug availability or affordability.
The bill references 'a major food allergen' without defining it within the text, relying on existing definitions in the Federal Food, Drug, and Cosmetic Act (specifically 21 U.S.C. 321(qq)). Additionally, the applicability date is set to the earlier of a Secretary-determined date or two years post-enactment.
Section 2(a)(2)(A) and Section 2(b)
Why it matters:Referencing existing definitions is standard legislative practice for brevity and consistency. The 'whichever is earlier' clause is a common mechanism to ensure a timely effective date while allowing for regulatory flexibility for the implementing agency.
Case for: This approach ensures consistency with established allergen definitions, preventing confusion and leveraging existing regulatory frameworks. The flexible applicability date allows the FDA to prepare while ensuring the requirements are not indefinitely delayed, providing a clear deadline for industry.
Case against: A reader unfamiliar with the FD&C Act might not immediately grasp the full scope of 'major food allergen,' potentially underestimating the bill's impact. The two-year window, while allowing for preparation, might still be challenging for some manufacturers to fully implement.
Estimated impact: Clarifies that the bill covers the nine major food allergens already recognized by federal law, alongside gluten-containing grains. The two-year window provides a fixed maximum timeframe for industry compliance, ensuring the new rules take effect promptly.